Breast cancer
Progression after CDK4/6i + ET for HR+ HER2- MBC. What now?

Abby (59 years old)

Abby, 59 years old, works as a teacher in the primary school of her town. She was diagnosed with de novo metastatic breast cancer.

Assessment summary:

  • Postmenopausal
  • No relevant comorbidities or family history
  • Diagnosis de novo HR+ HER2- metastatic breast cancer with multiple bone and lymph node metastases (axillary, cervical, mediastinal)
    • Tumour biology (lymph node lesion): invasive carcinoma of NST, ER 30%, PgR 10%, HER2 IHC 1+, Ki67 40%
  • First-line treatment: CDK4/6i + letrozole
    • CT scan after 3 months: disease progression, with increase of all existing lesions; 2 new bone lesions

Which option would you choose for this patient?